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Background: Antipsychotic drugs may lead to side effects such as obesity, diabetes,
dyslipidemia, and cardiovascular disease. The current systematic review and network
meta-analysis analyzes and provides an update on the clinical performance of these
add-ons in comparison to placebo on body weight and body mass index (BMI)
reductions.
Methods: A comprehensive literature search was performed on electronic databases:
PubMed (1946-), Embase (1974-), Cochrane library (1992-), and OpenGrey (2000-)
until 31 July 2018. Network meta-analyses, comparing the body weight change, BMI
change and withdrawn due to adverse events of different pharmacological add-ons, was
performed using a multivariate meta-regression model with random-effects, adopting a
frequentist approach. To rank the prognosis for all add-ons, we used surface under the
cumulative ranking (SUCRA) values.
Outcomes: From 614 potential studies identified, 27 eligible studies (n = 1,349 subjects)
were included. All the studies demonstrated low to moderate risk of bias. For the
analysis of body weight change, all add-ons except Ranitidine showed significant weight
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reductions comparing to placebo. The effectiveness rank based on SUCRA results from
highest to lowest was Sibutramine, Topiramate, Metformin, Reboxetine, Ranitidine, and
placebo. A similar pattern was seen for BMI change. The analysis of safety outcome did
not detect significantly increased withdrawn number from the add-ons. Current evidence
showed relatively good tolerance and safety of using the pharmacological add-ons.
Interpretation: Topiramate and Metformin are effective add-on treatments in controlling
antipsychotic-induced weight gain, comparing to placebo. They are well tolerated in
short-term period. Although Sibutramine has the highest rank of the effectiveness,
its license has been withdrawn in many countries due to its adverse effects. Hence,
Sibutramine should not be adopted to treat antipsychotic-induced weight gain.
Keywords: antipsychotic-induced weight gain, network meta-analysis, pharmacological add-ons, topiramate,
metformin
INTRODUCTION
Antipsychotic drugs (APDs) may lead to side effects such as
obesity, diabetes, dyslipidemia, and cardiovascular disease. This
adverse effect cluster presents an obstacle in the treatment and
management of patients with schizophrenia or bipolar disorder,
and limits patient adherence to medication and consequently
adversely impacts treatment outcomes.
To counter the antipsychotic-induced weight gain, various
pharmacological add-ons were investigated. Taking antidiabetics
or antiobesity drugs as an adjuvant treatment, including
metformin, orlistat, sibutramine, and naltrexone, is a popular
approach for weight management and has been widely studied
(Baptista et al., 2006; Henderson et al., 2007; McElroy et al.,
2007; Joffe et al., 2008; Tchoukhine et al., 2011; Tek et al., 2014;
Anagnostou et al., 2016; Rado and von Ammon Cavanaugh,
2016; Vishnupriya et al., 2016; Wu et al., 2016; Handen et al.,
2017). Most of the studies reported significant reductions in
body weight. Gastrointestinal agents, especially antacids like
nizatidine, were reported may stop but not reduce the weight gain
(Atmaca et al., 2003, 2004; Assuncao et al., 2006). Topiramate, a
type of anticonvulsant, shows a negative association with body
weight gain and has been found to control antipsychotic-induced
weight gain for subjects with schizophrenia or bipolar disorder
(McElroy et al., 2007; Afshar et al., 2009; Wozniak et al., 2009;
Narula et al., 2010).
Until recently, no study has been published comparing various
pharmacological add-ons on antipsychotic-induced weight gain,
from both direct and indirect evidence. The current systematic
review and network meta-analysis analyzes and provides an
update on the clinical effectiveness and safety of these add-ons in
comparison to placebo on body weight, body mass index (BMI)
reductions and number of withdrawn due to adverse effects.
MATERIALS AND METHODS
Literature Search and Eligibility Criteria
A comprehensive literature search was performed on electronic
databases: PubMed (1946-), Embase (1974-), Cochrane library
(1992-), and OpenGrey (2000-) until 31 July 2018. The specific
concepts used in the search strategy were “antipsychotic agents”
and “weight.” We conducted literature search using Medical
Subject Headings (MeSH) or Emtree, and free text terms. There
were no restrictions on language. The bibliography listed in
review papers and included publications were also checked.
Two investigators (CjZ and QZ) independently screened
for eligible studies based on pre-defined eligibility criteria.
Randomized controlled trials (RCTs) that examined the
pharmacological interventions of weight management for
antipsychotics-induced obesity were included. To avoid
imprecise estimations, only those add-ons with at least two
RCTs studied were included. Non-randomized or observational
studies, case reports, commentaries, and letters-to-editors were
excluded.
Data Extraction and Quality Assessment
The following data were extracted from the included studies: (1)
study characteristics (publication year and patient population);
(2) baseline characteristics (mean age, number of males, follow-
up time, and ongoing antipsychotic treatment); and (3) outcome
events (weight change [kg], BMI change [kg/m2], and number of
withdrawn due to adverse events).
The quality of each study was evaluated, using the Cochrane
Collaboration Risk of Bias tool, by two independent investigators
(CjZ and QZ). Six domains were assessed for each RCT, including
random sequence generation, allocation concealment, blinding
of participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective reporting, and other sources
of bias. Each domain would be assigned a judgment of ‘Low
risk’ of bias, ‘High risk’ of bias, or ‘Unclear risk’ of bias. Any
disagreement in quality assessment was resolved by discussion
and consensus.
Statistical Analysis
A network geometry was constructed based on the included
studies for each add-on treatment. Each node represented an
add-on and its size was weighted by the number of subjects of
each add-on. The connecting line between two nodes meant a
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direct comparison existed and its thickness was determined by
the number of studies included.
Network meta-analysis, comparing the body weight change,
BMI change, and number of patients withdrawn due to adverse
events among different pharmacological add-ons, was performed
using a multivariate meta-regression model with random-
effects, adopting a frequentist approach (Higgins et al., 2012;
White et al., 2012). The model allows for the inclusion of
potential covariates, and accounts for the correlations from
multi-arm trials, and mean difference (MD) for weight and BMI
change and risk ratio (RR) for number of withdrawn due to
adverse events of each add-on treatment was estimated (White,
2011).
To rank the prognosis for all the add-ons, we used surface
under the cumulative ranking (SUCRA) values (Salanti et al.,
2011). Rank probabilities of all the add-ons were first estimated
under a Bayesian framework. A step function was then applied
to summarize the cumulative ranking for estimating the SUCRA
values of each add-on, ranging from 0 to 1. Thus, large SUCRA
values indicated a better prognosis.
The node-splitting approach and inconsistency model were
used to test the consistency assumption (Dias et al., 2010). The
former method involved fitting a series of node-splitting models,
with one model for each add-on pairing for which there was
direct and indirect evidence (Donegan et al., 2013). The latter
method first fits an inconsistency model and then conduct a
Wald test to check whether there is significant inconsistency
among the included studies (White, 2015). Sensitivity analysis
was conducted by (1) excluding studies with both “blinding
of participants and personnel” and “blinding of outcome
assessment” ranked as “Unclear” or “High risk,” as the outcomes
(i.e., measurement of weight and BMI) were likely to be
biased due to these two key components, and (2) limiting
the analysis on studies with less than 12 months’ follow-
up.
The network meta-analyses were implemented by Stata/MP 13
with network and network graphs package (Chaimani et al., 2013;
StataCorp, 2013; White, 2015).
RESULTS
Study Characteristics and Network
Geometry
From 614 potential studies identified from the initial search,
27 randomized controlled trials (n = 1,349 subjects) satisfied
inclusion/exclusion criteria and were included in this meta-
analysis (Figure 1 and Table 1; Lopez-Mato et al., 2003;
Poyurovsky et al., 2003, 2007, 2013; Henderson et al., 2005,
2007; Ko et al., 2005; Nickel et al., 2005; Klein et al., 2006;
Baptista et al., 2007, 2008; McElroy et al., 2007; Arman
et al., 2008; Wu et al., 2008, 2012; Afshar et al., 2009;
Carrizo et al., 2009; Narula et al., 2010; Wang et al., 2012;
Chen et al., 2013; Jarskog et al., 2013; Ranjbar et al., 2013;
Biedermann et al., 2014; de Silva et al., 2015; Anagnostou
et al., 2016; Mehta and Ram, 2016; Rado and von Ammon
Cavanaugh, 2016). The mean age was 31.9 years old and 48.6%
(n = 655) were males. The follow-up period was relatively short,
ranging from 6 to 26 weeks. Among the included studies, one
study recruited patients with autism spectrum disorder (ASD),
two for patients with bipolar disorder, 20 for patients with
schizophrenia and schizophrenic conditions and four for patients
with various psychosis. Efficacy results on Topiramate were
reported in 4 studies, Metformin in 13 studies, Reboxetine in
3 studies, Ranitidine in 2 studies, and Sibutramine in 4 studies
(Figure 1).
The network geometry was constructed (Figure 2). Most
of the studies demonstrated low to moderate risk of bias in
the six domains assessed. However, due to missing information
or inappropriate methods on randomization, four studies were
ranked as “Unclear” or “High risk” in “Random sequence
generation” (Supplementary Figure S1).
Effectiveness on Body Weight Change
For outcome of body weight change, 27 studies were included
in the analysis. All the add-ons, except Ranitidine, showed
significant weight reductions compared to placebo. Topiramate
showed the lowest mean difference (MD) −3.07 kg (95%
CI: −5.57, −0.48), followed by Sibutramine MD = −2.97 kg
(95% CI: −4.18, −1.77), Metformin MD = −2.50 kg (95%
CI: −3.21, −1.80), and Reboxetine MD = −2.25 kg (95%
CI: −3.54, −0.95) (Table 2). Results from both the node-
splitting method and inconsistency model showed no evidence
on the violation of consistency assumption between direct
and indirect comparisons. As shown in Supplementary
Figure S2, the pooled estimates were quite similar between
consistency model (red diamonds) and inconsistency
model (green diamonds), indicating that inconsistency
covariates did not yield a significantly better fitting. The
p-value = 0.166 from the Wald test further confirmed
that there is no evidence on the violation of consistency
assumption.
To confirm the rank of effectiveness on body weight reduction,
SUCRA values were calculated, and the rank from highest to
lowest was Sibutramine, Topiramate, Metformin, Reboxetine,
Ranitidine, and placebo (Table 3).
In the sensitivity analysis by excluding the eight studies,
similar pooled estimates were obtained and the rank order
remained the same. Further sensitivity analysis by excluding
studies with less than 12 months’ follow-up showed that
metformin, sibutramine and topiramate were consistently
significant with a reduction in body weight at −2.54 (95% CI:
−3.29, −1.79), −2.98 (95% CI: −4.34, −1.62), and −2.95 (95%
CI: −5.87, −0.03), respectively. Ranitidine did not show any
significant reduction in body weight, which was consistent to the
main result as well. However, Reboxetine was reported only in
studies with less than 12 months’ follow-up, we were unable to
check its sensitivity results.
Effectiveness on BMI Change
For the BMI change outcome, 24 studies were included
in the analysis. A similar pattern was seen for BMI
change, where all add-ons except cardiac Ranitidine
showed statistically significant BMI reductions comparing
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FIGURE 1 | PRISMA flowchart of study selection.
Frontiers in Pharmacology | www.frontiersin.org 4 November 2018 | Volume 9 | Article 1393
fphar-09-01393 November 27, 2018 Time: 16:45 # 5
Zhuo et al. Add-Ons for Controlling Antipsychotic-Induced Weight Gain
TABLE 1 | Summary of study characteristics of included study.
Study Country Main diseases Sample size Mean age (SD) Ongoing
treatment
Intervention and
control
Follow-up
(weeks)
Afshar et al., 2009 Iran Schizophrenia I: 16 (9, 56%)
C: 16 (11, 69%)
I: 37.5 (5.7)
C: 38.1 (4.6)
Clo I: Topiramate
C: Placebo
8
Anagnostou et al.,
2016
Canada ASD I: 28 (21, 75%)
C: 32 (24, 75%)
I: 12.9 (2.85)
C: 12.7 (2.64)
Mixed I: Metformin
C: Placebo
16
Arman et al., 2008 Iran Schizophrenia I: 16 (11, 69%)
C: 16 (10, 63%)
I: 11.25 (2.46)
C: 8.93 (4.28)
Ris I: Metformin
C: Placebo
12
Baptista et al., 2007 Canada Schizophrenia I: 36 (23, 64%)
C: 36 (19, 53%)
I: 43.8 (11.4)
C: 44.5 (12.0)
Ola I: Metformin
C: Placebo
12
Baptista et al., 2008 Canada Schizophrenia I: 13 (6, 46%)
C: 15 (8, 53%)
I: 45.6 (8.0)
C: 49.4 (12.3)
Ola I: Metformin
C: Placebo
12
Biedermann et al.,
2014
Austria Schizophrenia I: 6 (, 0%)
C: 5 (, 0%)
I: 19-65
C: 19-65
Mixed I: Sibutramine
C: Placebo
24
Carrizo et al., 2009 Venezuela Schizophrenia I: 24 (, 0%)
C: 30 (, 0%)
I: 39.6 (9.7)
C: 38.3 (8.7)
Clo I: Metformin
C: Placebo
14
Chen et al., 2013 Taiwan Schizophrenia I: 28 (13, 46%)
C: 27 (15, 56%)
I: 41.8 (7.2)
C: 41.4 (10.2)
Clo I: Metformin
C: Placebo
24
de Silva et al., 2015 Sri Lanka Schizophrenia I: 34 (6, 18%)
C: 32 (8, 25%)
I: 33.5 (9.9)
C: 35.3 (10.7)
Mixed I: Metformin
C: Placebo
26
Henderson et al., 2005 United States Schizophrenia I: 19 (12, 63%)
C: 18 (11, 61%)
I: 43.2 (10.6)
C: 40.7 (9.9)
Ola I: Sibutramine
C: Placebo
12
Henderson et al., 2007 United States Schizophrenia I: 11 (8, 73%)
C: 10 (8, 80%)
I: 41.0 (10.0)
C: 39.0 (10.0)
Clo I: Sibutramine
C: Placebo
12
Jarskog et al., 2013 United States Schizophrenia I: 75 (52, 69%)
C: 71 (49, 69%)
I: 41.4 (11.5)
C: 45.0 (10.3)
Mixed I: Metformin
C: Placebo
16
Klein et al., 2006 United States BPD I: 18 (9, 50%)
C: 20 (12, 60%)
I: 12.9 (2.4)
C: 13.3 (2.4)
Mixed I: Metformin
C: Placebo
16
Ko et al., 2005 Korea Schizophrenia I: 17 (7, 41%)
C: 20 (12, 60%)
I: 35.3 (9.75)
C: 37.6 (7.98)
Mixed I: Topiramate
C: Placebo
12
Lopez-Mato et al.,
2003
Spain Mixed I: 29
C: 28
I: NA
C: NA
Ola I: Ranitidine
C: Placebo
16
McElroy et al., 2007 United States BPD I: 18 (4, 22%)
C: 28 (7, 25%)
I: 40.6 (13.9)
C: 41.7 (11.8)
Mixed I: Sibutramine
C: Topiramate
24
Mehta and Ram, 2016 India Schizophrenia I: 25 (22, 88%)
C: 25 (23, 92%)
I: 30.3 (7.4)
C: 32.2 (8.3)
Ola I: Ranitidine
C: Placebo
8
Narula et al., 2010 India Schizophrenia I: 33 (22, 67%)
C: 34 (22, 65%)
I: 31.2 (9.7)
C: 31.0 (10.1)
Ola I: Topiramate
C: Placebo
12
Nickel et al., 2005 Germany Mixed I: 25 (0, 0%)
C: 18 (0, 0%)
I: 35.2 (8.2)
C: 34.5 (9.2)
Ola I: Topiramate
C: Placebo
10
Poyurovsky et al., 2007 Israel Schizophrenia I: 31 (23, 74%)
C: 28 (15, 54%)
I: 30.3 (8.5)
C: 29.5 (7.2)
Ola I: Reboxetine
C: Placebo
6
Poyurovsky et al., 2013 Israel Schizophrenia I: 29 (23, 79%)
C: 14 (12, 86%)
I: 33.2 (9.7)
C: 31.0 (8.2)
Ola I: Reboxetine
C: Placebo
6
Poyurovsky et al., 2003 Israel Schizophrenia I: 10 (6, 60%)
C: 10 (5, 50%)
I: 34.6 (13.0)
C: 26.5 (6.7)
Ola I: Reboxetine
C: Placebo
6
Rado and von Ammon
Cavanaugh, 2016
United States Mixed I: 12 (7, 58%)
C: 13 (5, 38%)
I: 33.5 (10.1)
C: 39.08 (8.62)
Ola I: Metformin
C: Placebo
24
Ranjbar et al., 2013 Iran Schizophrenia I: 25 (16, 64%)
C: 27 (17, 63%)
I: 38.5 (11.2)
C: 37.7 (11)
Ola I: Ranitidine
C: Placebo
16
Wang et al., 2012 China Schizophrenia I: 32 (15, 47%)
C: 34 (19, 56%)
I: 26.8 (4.2)
C: 25.6 (4.6)
Mixed I: Metformin
C: Placebo
12
Wu et al., 2012 China Schizophrenia I: 42 (0, 0%)
C: 42 (0, 0%)
I: 25.7 (4.8)
C: 27.1 (4.2)
Mixed I: Metformin
C: Placebo
24
Wu et al., 2008 China Schizophrenia I: 18 (10, 56%)
C: 19 (10, 53%)
I: 25.4 (3.9)
C: 24.8 (3.5)
Ola I: Metformin
C: Placebo
12
Clo, clozapine; Ola, olanzapine; Ris, risperidone.
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FIGURE 2 | Network geometry of included studies (top, weight change;
below, withdrawn due to adverse event).
to placebo. In particular, anticonvulsant presented the
highest reduction, reaching MD = −1.59 kg/m2 (95%
CI: −2.65, −0.54) (Table 2). SUCRA results showed a
consistent order from the highest to lowest: Topiramate,
Sibutramine, Metformin, Reboxetine, Ranitidine, and placebo
(Table 3).
Tolerance and Safety on Number of
Withdrawn Due to Adverse Events
To assess the tolerance and safety of add-on treatments, we
estimated the pooled RR for all add-ons comparing to placebo. All
the pooled RR had wide 95% CI due to a relatively low prevalence
of patients withdrawn due to adverse events in each included
study. Among them, Topiramate had the highest but statistically
insignificant RR 1.88 (95% CI: 0.44, 7.94). Therefore, current
evidence did not reveal a significantly higher safety issue by using
add-ons in the short-term period follow-up.
DISCUSSION
Current published systematic reviews on add-ons controlling
APD-induced weight gain were either focused on one particular
medication (e.g., metformin) (Housel et al., 2009; Miller, 2009;
Prajapati, 2014; de Silva et al., 2016; Siskind et al., 2016), or
indirectly compared different medications in a qualitative way,
i.e., ranking the treatment effects simply based on the pair-
wise meta-analyses results (Miller, 2009; Maayan et al., 2010;
De Hert et al., 2012; Kishi et al., 2014; Mizuno et al., 2014;
Choi, 2015; Whitney et al., 2015; Zimbron et al., 2016). The
current review aims to quantitatively synthesize the weight and
BMI reduction effects through a combination of both direct
and indirect evidence. A total of 27 studies were included,
among which only one study reported head-to-head comparisons
between any two of the add-ons (McElroy et al., 2007). Hence,
by using network meta-analysis we were able to allow indirect
comparisons between the add-ons as well as against placebo.
Notably, although our results showed that Sibutramine
ranked first in body weight reduction and second in BMI
reduction, its license has been withdrawn in many countries
due to its adverse effects. Hence, Sibutramine should not be
adopted to treat antipsychotic-induced weight gain. Sibutramine
is an antiobesity medication affecting both serotonin and
norepinephrine reuptake (Henderson et al., 2007). Although
the tolerance in this current review is not significantly lower
than placebo, the Sibutramine Cardiovascular Outcomes Trial
confirmed that subjects with preexisting cardiovascular disease
on long-term treatment with Sibutramine had a significantly
increased risk for non-fatal myocardial infarction and non-fatal
stroke but not cardiovascular death or all-cause mortality (Torp-
Pedersen et al., 2007). Converging with previous studies, we
TABLE 2 | Summary of results on body weight change and BMI change.
Metformin −0.61 (−1.51, 0.30) −0.26 (−0.93, 0.40) 0.23 (−0.78, 1.25) 0.59 (−0.51, 1.69) −1.01 (−1.32, −0.69)∗
−2.40 (−4.44, −0.36)∗ Ranitidine 0.34 (−0.68, 1.37) 0.84 (−0.43, 2.11) 1.19 (−0.14, 2.53) −0.40 (−1.25, 0.45)
−0.26 (−1.70, 1.18) 2.14 (−0.17, 4.46) Reboxetine 0.50 (−0.63, 1.62) 0.85 (−0.35, 2.06) −0.74 (−1.33, −0.16)∗
0.47 (−0.88, 1.83) 2.87 (0.61, 5.14)∗ 0.73 (−1.02, 2.47) Sibutramine 0.35 (−0.72, 1.42) −1.24 (−2.21, −0.27)∗
0.57 (−2.08, 3.22) 2.97 (−0.25, 6.19) 0.83 (−2.05, 3.70) 0.10 (−2.42, 2.62) Topiramate −1.59 (−2.65, −0.54)∗
−2.50 (−3.21, −1.80)∗ −0.10 (−2.04, 1.83) −2.25 (−3.54, −0.95)∗ −2.97 (−4.18, −1.77)∗ −3.07 (−5.67, −0.48)∗ Placebo
Bottom left panel reported the pooled mean difference (MD) of body weight changes from network meta-analysis, and the name to the right of each MD was the reference
add-on.
Top right panel reported the pooled MD of BMI changes from network meta-analysis, and the name below each MD was the reference add-on; ∗statistical significant with
p-value < 0.05.
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TABLE 3 | Summary of results from SUCRA.
Add-ons Body weight reduction BMI reduction Withdrawn due to adverse event
SUCRA Rank SUCRA Rank SUCRA Rank
Sibutramine 80.0 1 72.7 2 65.0 2
Topiramate 77.2 2 89.1 1 28.8 5
Metformin 64.2 3 63.5 3 34.5 4
Reboxetine 56.8 4 44.8 4 66.3 1
Ranitidine 12.4 5 26.1 5 NA NA
Placebo 9.2 6 3.8 6 65.0 2
strongly suggest that we should not adopt sibutramine to treat
antipsychotic-induced weight gain.
Some longitudinal studies suggest using body composition
data rather than only measurements of body weight for
understanding the relationship with disability and mortality
(Seidell and Visscher, 2000; Myrskylä and Chang, 2009).
Current systematic reviews included BMI changes as one
of the efficacy outcomes as well. Topiramate showed
the best performance on controlling BMI based on our
meta-analysis. It is an anticonvulsant blocking α-amino-3-
hydroxy-5-methylisoxazole-4-propionic (AMPA)/kainate-gated
ion and sodium channels and positively modulate GABA
receptors (White et al., 1997). The side effect of weight loss
when using Topiramate has been documented and been
applied to treatment for adiposity caused by eating disorders
(Anghelescu et al., 2002; Levy et al., 2002). In our current
review, it showed excellent weight and BMI reduction. The
adverse effects, reported in the included studies, were mild to
moderate without serious adverse effects. Paresthesia was the
most common side effect observed in most of the included
studies (Ko et al., 2005; Afshar et al., 2009; Narula et al.,
2010).
Metformin, a major antidiabetic medication, was widely
studied in the literature on controlling antipsychotic induced
weight gain and was proven to be effective (de Silva et al.,
2016; Siskind et al., 2016). Klein et al. reported its efficacy
of reducing weight gain in children and adolescents who
were treated with olanzapine as well (Klein et al., 2006).
One of the reasons may be explained by its effects in
enhancing the glycaemic control effects of insulin, antagonizing
glucagon, and suppressing gluconeogenesis and glycogenolysis
(Wiernsperger and Bailey, 1999). Similar reduction in BMI was
reported in a recent pair-wise meta-analysis at −0.89 (95%
CI −1.20, −0.58) (Zimbron et al., 2016). Although the rank
of antidiabetics were generally lower than Topiramate and
Sibutramine, Metformin showed long-term tolerance and weight
loss effect for type 2 diabetes patients, even over 10 years (Ratner
et al., 2006; Diabetes Prevention Program Research Group,
2012). This evidence highlights the potential long-term use of
metformin for antipsychotic-induced weight gain patients as
well.
Of note, apart from pharmacological add-ons, nutritional
and behavioral interventions are important for weight control.
A recent systematic review reported that non-pharmacological
interventions, either individual or group interventions, or
cognitive–behavioral therapy as well as nutritional counseling
were effective in reducing or attenuating antipsychotic-induced
weight gain compared with treatment as usual, with treatment
effects maintained over follow-up (Alvarez-Jimenez et al., 2008).
Our review did not consider including these interventions
due to high heterogeneity from study to study, but the
combination of both pharmacological and non-pharmacological
interventions might be promising for further controlling the
weight gain.
The current evidence in our study showed relatively good
tolerance and safety of using these pharmacological add-ons.
However, given that most of the included RCTs had relatively
short period of follow-up, further evidence on potential long-
term adverse effects are needed.
Study Limitations
In total, only 6 out of 27 included RCTs followed up more than
half a year. The relative short period of follow-up time limited
the ability of our findings to be extrapolated to longer periods,
as the adherence of medication, etc., may alter the effectiveness
or the rank in the long run. Therefore, primary studies on
the long-term effects of pharmacological add-ons are needed.
As mentioned above, nutritional and behavioral intervention,
which were not included in the review, are alternatives for
controlling APD-induced weight gain. We would expect primary
and secondary studies on evaluating the rank of effectiveness
on both intervention, and additive benefits when combining
both.
CONCLUSION
Topiramate, and Metformin are effective add-on treatments in
controlling antipsychotic-induced weight gain, comparing to
placebo. They are well tolerated over a short-term period. More
importantly, we propose to conduct a large sample long-term
cohort study to explore the optimal treatment methods for
treating antipsychotic-induced weight gain in long term.
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